EP0830338B1 - Method of making 3-(aminomethyl)-5-methylhexanoic acid - Google Patents

Method of making 3-(aminomethyl)-5-methylhexanoic acid Download PDF

Info

Publication number
EP0830338B1
EP0830338B1 EP96914618A EP96914618A EP0830338B1 EP 0830338 B1 EP0830338 B1 EP 0830338B1 EP 96914618 A EP96914618 A EP 96914618A EP 96914618 A EP96914618 A EP 96914618A EP 0830338 B1 EP0830338 B1 EP 0830338B1
Authority
EP
European Patent Office
Prior art keywords
aminomethyl
acid
methylhexanoic acid
water
methylhexanoic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP96914618A
Other languages
German (de)
French (fr)
Other versions
EP0830338A1 (en
Inventor
Todd Michel Grote
Brian Keith Huckabee
Thomas Mulhern
Denis Martin Sobieray
Robert Daniel Titus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Priority to SI9630390T priority Critical patent/SI0830338T1/en
Publication of EP0830338A1 publication Critical patent/EP0830338A1/en
Application granted granted Critical
Publication of EP0830338B1 publication Critical patent/EP0830338B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/30—Preparation of optical isomers
    • C07C227/34—Preparation of optical isomers by separation of optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/04—Formation of amino groups in compounds containing carboxyl groups
    • C07C227/10—Formation of amino groups in compounds containing carboxyl groups with simultaneously increasing the number of carbon atoms in the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/19—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same saturated acyclic carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/19—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same saturated acyclic carbon skeleton
    • C07C255/22—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same saturated acyclic carbon skeleton containing cyano groups and at least two carboxyl groups bound to the carbon skeleton

Definitions

  • This invention relates to a method of making ( ⁇ )-3-(aminomethyl)-5-methylhexanoic acid and to a method of obtaining (S)-3-(aminomethyl)-5-methylhexanoic acid from ( ⁇ )-3-(aminomethyl)-5-methylhexanoic acid.
  • 3-(Aminomethyl)-5-methylhexanoic acid which is also called ⁇ -isobutyl- ⁇ -aminobutyric acid or isobutyl-GABA, is a potent anticonvulsant.
  • Isobutyl-GABA is related to the endogenous inhibitory neurotransmitter ⁇ -aminobutyric acid or GABA, which is involved in the regulation of brain neuronal activity.
  • convulsions can be controlled by controlling the metabolism of the neurotransmitter ⁇ -aminobutyric acid.
  • concentration of GABA diminishes below a threshold level in the brain, convulsions result (Karlsson A., et al., Biochem. Pharmacol. , 1974;23:3053-3061), and when the GABA level rises in the brain during convulsions, the seizures terminate (Hayashi T., Physiol. (London), 1959;145:570-578).
  • seizure means excessive unsynchronized neuronal activity that disrupts normal function.
  • GABA L-glutamic acid decarboxylase
  • (S)-3-(aminomethyl)-5-methylhexanoic acid has been prepared by two synthetic routes. These routes each use reactions that require n -butyllithium, and both routes contain a step that must be carried out at low temperatures ( ⁇ -35°C) under carefully controlled conditions.
  • These synthetic routes include the use of (4R,5S)-4-methyl-5-phenyl-2-oxazolidinone as a chiral auxiliary to introduce the stereochemical configuration needed in the final product. See, for example, United States Serial No. 08/064,285, which is hereby incorporated by reference. Although these routes provide the target compound in high enantiomeric purity, they are difficult to conduct on large-scale and use expensive reagents which are difficult to handle.
  • ( ⁇ )-isobutyl GABA can be synthesized in accordance with Andruszkiewicz, et al., Synthesis , 1989;953.
  • the synthesis described therein uses potentially unstable nitro compounds, including nitromethane, and an intermediate containing a nitro functional group, which is reduced to an amine in a potentially exothermic and hazardous reaction.
  • the synthesis also uses lithium bis(trimethylsilylamide) at -78°C.
  • the present method does not use nitro compounds, require low temperatures, or require strongly basic conditions.
  • the present invention provides an efficient synthesis of isobutyl-GABA and provides for the resolution of racemic isobutyl-GABA to obtain the S-stereoisomer of isobutyl-GABA that avoids the above-identified problems.
  • the present invention provides a method of making ( ⁇ )-3-(aminomethyl)-5-methylhexanoic acid and its S-form, (S)-3-(aminomethyl)-5-methylhexanoic acid, the method comprising:
  • decarboxylating and hydrolyzing steps c.) and d.) are combined to form the carboxylate salt.
  • the present invention also provides for a method wherein the resolution step comprises:
  • the present invention also provides for a method wherein the resolution step comprises:
  • Preferred is a resolution method wherein the ( ⁇ )-3-(aminomethyl)-5-methylhexanoic acid and (S)- or (R)-mandelic acid are combined in a 3% v/v solution of water in isopropyl alcohol.
  • polar solvents are dimethylsulfoxide and tetrahydrofuran.
  • the invention further provides a compound having the formula wherein R 1 and R 2 are the same or different and are hydrogen, C 1 -C 6 alkyl, aryl, benzyl or C 3 -C 6 cycloalkyl, preferably a compound wherein R 1 and R 2 are ethyl.
  • the invention further provides a compound having the formula wherein M is hydrogen, an alkali metal, or an alkaline earth metal and R 1 is C 1 -C 6 alkyl, aryl, benzyl, or C 3 -C 6 cycloalkyl, preferred is a compound wherein M is sodium or potassium.
  • the present invention provides an efficient synthesis of racemic isobutyl-GABA and a method for obtaining (S)-isobutyl-GABA from racemic isobutyl-GABA.
  • R 1 and R 2 are the same or different and are hydrogen, C 1 -C 6 alkyl, aryl, benzyl or C 3 -C 6 cycloalkyl; and M is hydrogen, an alkali metal, or an alkaline earth metal.
  • Scheme I illustrates a method of making ( ⁇ )-3-(aminomethyl)-5-methylhexanoic acid (VII or racemic 3-(aminomethyl)-5-methylhexanoic acid), the method comprising condensing isovaleraldehyde (I) with (II) to form (III); reacting (III) with a cyanide source to form (IV); decarboxylating (IV) to form (V); hydrolyzing (V) with an alkali metal or alkaline earth metal hydroxide to form (VI); and hydrogenating (VI) to form ( ⁇ )-3-(aminomethyl)-5-methylhexanoic acid (VII).
  • ( ⁇ )-3-(aminomethyl)-5-methylhexanoic acid can be made by condensing isovaleraldehyde (I) with (II) to form (III); reacting (III) with a cyanide source to form (IV); hydrolyzing and decarboxylating (IV) (step g) to form (VI); and hydrogenating (VI) to form ( ⁇ )-3-(aminomethyl)-5-methylhexanoic acid (VII).
  • Also provided by the present invention is a method for obtaining (S)-3-(aminomethyl)-5-methylhexanoic acid (IX) from ( ⁇ )-3-(aminomethyl)-5-methylhexanoic acid (VII), the method comprising combining ( ⁇ )-3-(aminomethyl)-5-methylhexanoic acid and (S)-mandelic acid in water, an alcohol or a mixture of water and an alcohol; allowing a precipitate to form; introducing the precipitate into a polar aprotic solvent, or a polar aprotic solvent and water, to form a slurry; and collecting the solid from the slurry.
  • isovaleraldehyde is condensed with wherein R 1 and R 2 are the same or different and are hydrogen C 1 -C 6 alkyl, aryl, benzyl, or C 3 -C 6 cycloalkyl.
  • This type of reaction is known to those skilled in the art as a Knoevenagel Condensation, and the conditions under which a Knoevenagel Condensation can be carried out are well known to those skilled in the art.
  • the condensation can be achieved using a catalytic amount of a base such as di- n -propylamine.
  • Other suitable catalysts are known in the literature.
  • catalysts include pyrrolidine, ⁇ -alanine, ammonium acetate, di-isoproplylamine, and di-n-propylamine. These basic catalysts can also be used in combination with an acid such as p-toluene sulfonic acid or acetic acid.
  • a preferred catalyst system in the present method is di- n -propylamine and acetic acid.
  • reaction is run in a refluxing hydrocarbon solvent including, but not limited to, toluene, hexane, heptane, methyl tert -butyl ether or cyclohexane, with the azeotropic removal of water.
  • a preferred solvent is hexane.
  • olefin regioisomers can also be formed in the reaction, but are converted to the desired product in a subsequent step in the reaction sequence.
  • C 1 -C 6 alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert -butyl, pentyl and hexyl.
  • Representative examples of C 3 -C 6 cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • Representative examples of aryl groups include phenyl and substituted phenyl, naphthyl, pridinyl, and the like. The aryl moiety may be substituted with one or more substituents, which can be the same or different.
  • R 1 and R 2 are ethyl.
  • the isovaleraldehyde and are added to the solvent along with the catalyst, and refluxed with azeotropic removal of water. It is also contemplated that additional catalyst may be added when the rate of azeotropic water collection slows. The progress of the condensation reaction may be monitored by methods well known in the art. A preferred monitoring method is gas chromatography (GC).
  • GC gas chromatography
  • a cyanide source In another step of the present method, is reacted with a cyanide source to form
  • a cyanide source in general, is reacted with a cyanide source in a polar protic solvent such as ethanol, methanol, n-propanol, isopropanol, a mixture of water and alcohols, or polar aprotic solvents such as dimethylsulfoxide (DMSO) or DMSO/water, and then treated with an acid.
  • suitable cyanide sources include, but are not limited to, hydrogen cyanide, acetone cyanohydrin or an alkali metal or alkaline earth metal cyanide, such as sodium cyanide, potassium cyanide, or magnesium cyanide.
  • the in this step may be used in the next step without purification, i.e. in crude form, or it may be purified.
  • suitable acids are acetic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, benzoic acid, mandelic acid, p-toluenesulfonic acid, and the like.
  • suitable solvents include mixtures of water and a polar solvent such as ethanol or dimethylsulfoxide (DMSO).
  • suitable salts include alkali metal and alkaline earth metal halides such as sodium chloride and alkali metal and alkaline earth metal cyanides such as sodium cyanide, magnesium cyanide, and the like.
  • the alkali or alkaline earth metal hydroxide can be any alkali or alkaline earth metal hydroxide known to those skilled in the art.
  • suitable alkali metal hydroxides include sodium hydroxide, lithium hydroxide, and potassium hydroxide.
  • suitable alkaline earth metal hydroxides include calcium hydroxide and magnesium hydroxide.
  • the reaction is usually run in a suitable protic solvent such as water or a mixture of water and a polar protic solvent such as methanol, ethanol, or isopropanol.
  • the carboxylate salt can be reduced to give the alkali or alkaline earth metal salt of ( ⁇ )-3-(aminomethyl)-5-methylhexanoic acid.
  • the carboxylate salt can be protonated with mineral acids or carboxylic acids to give the carboxylic acid and then the nitrile group of the carboxylic acid can be reduced. Conversely, the nitrile group of the carboxylate salt can be reduced, and subsequently protonated to form the carboxylic acid.
  • the salt can be treated with mineral acids or carboxylic acids to give ( ⁇ )-3-(aminomethyl)-5-methylhexanoic acid. Those skilled in the art are familiar with the reduction of nitrile functional groups.
  • One common method of reducing a nitrile uses a hydrogenation catalyst, such as sponge nickel, in the presence of hydrogen.
  • a hydrogenation catalyst such as sponge nickel
  • Other catalysts include palladium, platium, rhodium, cobalt, and nickel.
  • the reaction is run in a solvent system such as a mixture of water and a polar protic solvent.
  • the amino carboxylate formed after nitrile reduction can be obtained in the acid form by treating the amino carboxylate with an acid.
  • the mineral acids such as hydrochloric acid can be used.
  • Carboxylic acids, such as acetic acid can also be used.
  • the acid is acetic acid
  • MOAc as a byproduct formed by the reaction is MOAc where M is an alkali metal ion (Na, K, and the like), and OAc is an acetate ion.
  • MOAc is more soluble in aqueous alcoholic solvents than inorganic salts such as sodium chloride, potassium chloride, and the like.
  • the cyano acid may also be reduced using a suitable hydrogenation catalyst, such as sponge nickel and hydrogen, in a polar solvent such as methanol, ethanol, or isopropanol in combination with ammonia or a mixture of ammonia and water.
  • suitable hydrogenation catalysts include palladium, platium, rhodium, cobalt, and nickel.
  • a preferred method is taken to ( ⁇ )-3-(aminomethyl)-5-methylhexanoic acid without isolation of intermediates.
  • an alkali or alkaline earth metal hydroxide such as potassium hydroxide or sodium hydroxide in an alcohol solvent, which promotes decarboxylation.
  • Further hydrolysis using an alkali or alkaline earth metal hydroxide in water, an alcohol, or a mixture of water and an alcohol gives carboxylate (VI), which can be reduced with a hydrogenation catalyst followed by treatment with a mineral acid to give racemic 3-(aminomethyl)-5-methylhexanoic acid.
  • Racemic 3-(aminomethyl)-5-methylhexanoic acid can be resolved, i.e., the enantiomers separated, by selective crystallization with (S)-mandelic acid.
  • Racemic 3-(aminomethyl)-5-methylhexanoic acid and (S)-mandelic acid can be combined in a solvent such as water or an alcohol or a mixture of water and an alcohol to form a salt.
  • suitable alcohols include methanol, ethanol, n-propanol, isopropanol, n-butanol, tert -butanol, and the like.
  • the S,S salt precipitates from the solution, and the diastereomer, the R,S salt, stays in solution.
  • Diasteriomeric purity of the S,S salt can be enhanced by further crystallizations. Additional (S)-mandelic acid can be included in the recrystallizations to enhance diastereomeric enrichment. In general, an excess of mandelic acid is used. It is also noted that mandelic acid can be used in combination with another acid in accordance with the "Pope-Peachy" method known in the art.
  • Removal of (S)-mandelic acid from the salt to give enriched (S)-3-(aminomethyl)-5-methylhexanoic acid can be done using a polar aprotic solvent such as dimethylsulfoxide or mixtures of dimethylsulfoxide and water or tetrahydrofuran and water, at temperatures typically in the range of about 0°C to about 100°C.
  • a polar aprotic solvent such as dimethylsulfoxide or mixtures of dimethylsulfoxide and water or tetrahydrofuran and water
  • Trituration to obtain the S-enantiomer has the advantage that it is operationally simple and more economical than traditional acid/base or ion exchange methods.
  • (S)-3-(aminomethyl)-5-methyl-hexanoic acid can be obtained by combining ( ⁇ )-3-(aminomethyl)-5-methylhexanoic acid with (R)-mandelic acid to give the R,R salt which crystallizes out of the solution leaving the solution enriched in (S)-3-(aminomethyl)-5-methylhexanoic acid which can then be isolated from the solution by methods well known to those skilled in the art.
  • the (R)-mandelic salt of (S)-3-(aminomethyl)-5-methylhexanoic acid can be isolated as an intermediate, treated with a polar aprotic solvent or mixture of water and a polar aprotic solvent to give the (S)-3-(aminomethyl)-5-methylhexanoic acid.
  • R 1 and R 2 are the same or different and are hydrogen, C 1 -C 6 alkyl, aryl, benzyl or C 3 -C 6 cycloalkyl; where M is hydrogen, an alkali metal, or an alkaline earth metal; where R 1 is a defined above; and
  • Isovaleraldehyde (361.6 kg, 4198.3 mol) was combined with diethyl malonate (640.8 kg, 4000.7 mol), hexane (1000 L), di- n -propylamine (20.0 kg, 197.6 mol), and glacial acetic acid (24.0 kg, 399.7 mol) in a 4000 L vessel.
  • the mixture was heated to reflux (jacket temperature set at 90°C) with continuous removal of water until the rate of water collection slowed significantly (69.4 kg water was collected versus 72.0 kg expected by theory).
  • the mixture was heated to reflux (jacket temperature set at 90°C) with continuous removal of water for an additional 22.5 hours or until the reaction is judged complete by GC assay (>90% combined product and isomer).
  • the mixture was brought to ⁇ 40°C and was washed with water (2 ⁇ 800 L).
  • the organic layer was concentrated by atmospheric pressure distillation until most of the hexane was removed.
  • the remaining oil was further concentrated by vacuum distillation at 40°C for 2-18 hours.
  • the product was obtained as a colorless liquid (810.0 kg, 88.7% yield) and contained a mixture of olefin isomers (both of which are converted to the same product in the next synthetic step).
  • the major isomer is 2-carboxyethyl-5-methylhex-2-enoic acid, ethyl ester; the minor isomer (typically 10-13% by GC) is believed to be 2-carboxyethyl-5-methylhex-3-enoic acid, ethyl ester.
  • the organic extracts were combined with a vessel rinse (25 kg methyl tert -butyl ether) and was extracted with water (110 L). The water phase was discarded. The methyl tert -butyl ether phase was concentrated by atmospheric pressure distillation to a batch temperature of about 65°C. The batch was cooled to 30-40°C and further concentrated by vacuum distillation until the solvent content was acceptable ( ⁇ 5% methyl tert -butyl ether by area %GC analysis). The product was obtained as a brown oil (51.3 kg, 85.7%).
  • the batch was transferred to a hydrogenator containing sponge nickel (15.0 kg, 50% water wet), followed by a rinse of ethyl alcohol 2B (27 kg).
  • the mixture was treated with hydrogen at about 50 psi for about 19 hours (hydrogen uptake stopped).
  • the nickel was removed by filtration and the filter cake was rinsed with a mixture of 39 kg ethyl alcohol 2B and 111 L water.
  • To the filtrate was added glacial acetic acid (22.8 kg, 380 mol) maintaining the batch temperature less than 40°C.
  • the batch was heated to 70-75°C to dissolve the solids.
  • the batch was slowly cooled to 0-5°C to crystallize the product.
  • the solid was collected on a centrifuge and rinsed with 160 L isopropyl alcohol that was previously cooled to 0-5°C.
  • the product was characterized by HPLC and NMR.
  • the water content for this product was 9.51% by weight (Karl Fischer).
  • the product may contain a variable amount of water ranging from nearly anhydrous up to about 10.2% (monohydrate).
  • Description: White to off-white solid HPLC Assay: 102.05% w/w Melting Point: 166.0-167.5°C 1 H NMR (D 2 O, 200 MHz): ⁇ 0.86-0.90 (m, 6H), 1.21 (t, 2H, J 7.0 Hz), 1.62-1.69 (m, 1H), 2.12-2.35 (m, 3H), 2.94-3.00 (m, 2H).
  • the batch was concentrated by vacuum distillation to about 580 L volume. Water (100 L) was added and the distillation continued to a volume of about 510 L.
  • the batch was transferred to an 800 L hydrogenator containing 44.8 kg sponge nickel (50% water wet), along with a mixture of 20 L water and 30 kg ethyl alcohol 2B as a rinse.
  • the mixture was treated with hydrogen at about 50 psi for about 18-19 hours (hydrogen uptake stopped).
  • the filtrate was transferred to a 2000 L still containing 222 kg (3697 mol) glacial acetic acid at 50-60°C controlling the addition rate to control gas evolution and to maintain the temperature at 50-60°C.
  • a rinse of 40 L water was added to the batch and the temperature increased to 70-75°C to dissolve the solids.
  • the batch was slowly cooled to 0-5°C to crystallize the product.
  • the solid was collected on a centrifuge and rinsed with 570 L isopropyl alcohol.
  • the damp solid was dried in a vacuum tray drier under vacuum at 35-45°C (22 hours) to give 108.1 kg (72.7%) of racemic 3-aminomethyl-5-methylhexanoic acid.
  • the product was characterized by HPLC and NMR.
  • the product may contain variable amounts of water ranging from nearly anhydrous (1.68% by weight in this example) up to about 10.2% (monohydrate).
  • a solution of 3% v/v water in isopropyl alcohol was prepared by mixing water (9 kg) and isopropyl alcohol (291 L) in a 400 L reactor. This was repeated. The solvent was stored in plastic drums and used as necessary (described below).
  • the solid may optionally be dried at this stage or carried on as a solvent-wet solid).
  • the damp salt was charged to a 400 L still along with (S)-(+)-mandelic acid (5.8 kg, 38 mol) and 3% water/isopropyl alcohol (121 kg). The mixture was heated to dissolve the solids (about 65-80°C), cooled, and seeded if necessary, with S,S-salt to crystallize the mixture of diastereomeric mandelate salts further enriched in the S,S-isomer. The solid was collected on a centrifuge and rinsed with 3% water/isopropyl alcohol (33.3 kg). The solid may optionally be dried at this stage or carried on as a solvent-wet solid (S/R isomer ratio: 99.5% S:0.5% R).
  • the damp salt was transferred to a 400 L reactor with tetrahydrofuran (195 L) and water (10 kg). The mixture was warmed to 60-65°C, and cooled to 0-5°C.
  • the crude (S)-isobutyl GABA solid was collected on a centrifuge and rinsed with a mixture of tetrahydrofuran (28 L)/water (1 kg). The solid may optionally be dried at this stage or carried on as a solvent-wet solid (S/R isomer ratio: 100% S: ⁇ 0.05% R isomer (not detected)).
  • the damp solid was transferred to a 200 L still with isopropyl alcohol (113 L) and water (38 kg). The mixture was heated to dissolve the solids (about 75-80°C), filtered while hot, and cooled to 0-5°C to crystallize the (S)-isobutyl GABA. The solid was collected on a centrifuge and rinsed with 25 L isopropyl alcohol. The damp solid was dried in a vacuum tray drier under vacuum at 35-45°C to give 7.4 kg (S)-isobutyl GABA.
  • a solution of 3% v/v water in isopropyl alcohol was prepared by mixing water (5.7 kg) and isopropyl alcohol (184 L) in a 400 L reactor. The solvent was stored in plastic drums and used as necessary (described below).
  • a 2000 L reactor was charged with racemic 3-aminomethyl-5-methylhexanoic acid (117.6 kg, 673 mol).
  • a 2000 L still was charged with water (36 L), S-(+)-mandelic acid (153.0 kg, 1006 mol), and isopropyl alcohol (1170 L).
  • the mandelic acid mixture was heated to 55-65°C and the resulting solution was transferred to the reactor containing racemic 3-aminomethyl-5-methylhexanoic acid.
  • the batch was heated to 50-65°C just long enough to dissolve the solids.
  • the mixture was cooled to 40-45°C, seeded with S,S-salt (20 g), and further cooled to 20-25°C to crystallize the mixture of diastereomeric mandelate salts enriched in the S,S-isomer. After maintaining the temperature at 20-25°C for at least 12 hours, the solid was collected on a centrifuge and rinsed with 3% water/isopropanol solution (100 kg) prepared earlier.
  • the solid may optionally be dried at this stage or carried on as a solvent-wet solid.
  • the solvent-wet S,S-salt was charged to an 800 L reactor.
  • An 800 L still was charged with water (14.4 kg), (S)-(+)-mandelic acid (23.0 kg, 151 mol), and isopropyl alcohol (468 L).
  • the mandelic acid mixture was heated to 65-70°C, and the resulting solution was transferred to the reactor containing the solvent-wet salt.
  • the batch was heated to 60-70°C just long enough to dissolve the solids or, if solids do not dissolve, until batch temperature reached 70°C.
  • the mixture was cooled to 50-55°C. Seeding with S,S-salt at this temperature range is optional but is typically not needed to induce crystallization or further diastereomeric enrichment.
  • the batch was further cooled to 0-5°C to crystallize the mixture of diastereomeric mandelate salts enriched in the S,S-isomer. After maintaining the temperature at 0-5°C for at least 12 hours, the solid was collected on a centrifuge and rinsed with 3% water/isopropanol solution (100 kg) prepared earlier.
  • the solid may optionally be dried at this stage or carried on as a solvent-wet solid.
  • the solid may optionally be dried at this stage or carried on as a solvent-wet solid.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Seasonings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method of making (+/-)-3-(aminomethyl)-5-methylhexanoic acid that comprises condensing isovaleraldehyde with to form primarily reacting the with a cyanide source to form decarboxylating the to form hydrolyzing the with an alkali or alkaline earth metal hydroxide to form an alkali or alkaline earth metal carboxylate salt; and hydrogenating the alkali or alkaline earth metal carboxylate salt to form (+/-)-3-(aminomethyl)-5-methylhexanoic acid, wherein R1 and R2 are the same or different and are hydrogen, C1-C6 alkyl, aryl, benzyl, or C3-C6 cycloalkyl. The present invention also provides a method of making (+/-)-3-(aminomethyl)-5-methylhexanoic acid that comprises condensing isovaleraldehyde with to form primarily reacting the with a cyanide source to form decarboxylating the to form an alkali or alkaline earth metal carboxylate salt; and hydrogenating the alkali or alkaline earth metal carboxylate salt to form (+/-)-3-(aminomethyl)-5-methylhexanoic acid.

Description

This invention relates to a method of making (±)-3-(aminomethyl)-5-methylhexanoic acid and to a method of obtaining (S)-3-(aminomethyl)-5-methylhexanoic acid from (±)-3-(aminomethyl)-5-methylhexanoic acid.
BACKGROUND OF THE INVENTION
3-(Aminomethyl)-5-methylhexanoic acid, which is also called β-isobutyl-γ-aminobutyric acid or isobutyl-GABA, is a potent anticonvulsant. Isobutyl-GABA is related to the endogenous inhibitory neurotransmitter γ-aminobutyric acid or GABA, which is involved in the regulation of brain neuronal activity.
It is thought that convulsions can be controlled by controlling the metabolism of the neurotransmitter γ-aminobutyric acid. When the concentration of GABA diminishes below a threshold level in the brain, convulsions result (Karlsson A., et al., Biochem. Pharmacol., 1974;23:3053-3061), and when the GABA level rises in the brain during convulsions, the seizures terminate (Hayashi T., Physiol. (London), 1959;145:570-578). The term "seizure" means excessive unsynchronized neuronal activity that disrupts normal function.
Because of the importance of GABA as an inhibitory neurotransmitter, and its effect on convulsive states and other motor dysfunctions, a variety of approaches have been taken to increase the concentration of GABA in the brain. In one approach, compounds that activate L-glutamic acid decarboxylase (GAD) have been used to increase concentrations of GABA, as the concentrations of GAD and GABA vary in parallel and increased GAD concentrations result in increased GABA concentrations (Janssens de Varebeke P., et al., Biochem. Pharmacol., 1983;32:2751-2755; Loscher W., Biochem. Pharmacol., 1982;31:837-842; Phillips N., et al., Biochem. Pharmacol., 1982;31:2257-2261). For example, the compound (±)-3-(aminomethyl)-5-methylhexanoic acid, a GAD activator, has the ability to suppress seizures while avoiding the undesirable side effect of ataxia.
It has been discovered that the anticonvulsant effect of isobutyl-GABA is stereoselective. That is, the S-stereoisomer of isobutyl-GABA shows better anticonvulsant activity than the R-stereoisomer. See, for example, Yuen, et al., in Bioorganic & Medicinal Chemistry Letters, 1994;4(6):823-826. Thus, it would be beneficial to have an efficient process for the synthesis of the S-stereoisomer of isobutyl-GABA.
Presently, (S)-3-(aminomethyl)-5-methylhexanoic acid has been prepared by two synthetic routes. These routes each use reactions that require n-butyllithium, and both routes contain a step that must be carried out at low temperatures (≤-35°C) under carefully controlled conditions. These synthetic routes include the use of (4R,5S)-4-methyl-5-phenyl-2-oxazolidinone as a chiral auxiliary to introduce the stereochemical configuration needed in the final product. See, for example, United States Serial No. 08/064,285, which is hereby incorporated by reference. Although these routes provide the target compound in high enantiomeric purity, they are difficult to conduct on large-scale and use expensive reagents which are difficult to handle.
In addition, (±)-isobutyl GABA can be synthesized in accordance with Andruszkiewicz, et al., Synthesis, 1989;953. The synthesis described therein uses potentially unstable nitro compounds, including nitromethane, and an intermediate containing a nitro functional group, which is reduced to an amine in a potentially exothermic and hazardous reaction. The synthesis also uses lithium bis(trimethylsilylamide) at -78°C. The present method does not use nitro compounds, require low temperatures, or require strongly basic conditions.
In Ullmann's Encyclopedia of Industrial Chemistry Vol. 18 A (1991) page 182/183 and in Römpp-Chemie-Lexikon Vol. 4 (1991) page 2623 the resolution of certain optically pure enantiomers has been described. These documents, however, do not mention the resolution of γ-amino acids. Furthermore the processes disclosed require the protection of the amino acids by additional process steps.
The present invention provides an efficient synthesis of isobutyl-GABA and provides for the resolution of racemic isobutyl-GABA to obtain the S-stereoisomer of isobutyl-GABA that avoids the above-identified problems.
The present invention provides a method of making (±)-3-(aminomethyl)-5-methylhexanoic acid and its S-form, (S)-3-(aminomethyl)-5-methylhexanoic acid, the method comprising:
  • a. condensing isovaleraldehyde with
    Figure 00040001
    to form primarily
    Figure 00040002
  • b. reacting the
    Figure 00040003
    with a cyanide source to form
    Figure 00040004
  • c. decarboxylating the
    Figure 00050001
    to form
    Figure 00050002
  • d. hydrolyzing the
    Figure 00050003
    with an alkali or alkaline earth metal hydroxide to form an alkali or alkaline earth metal carboxylate salt;
  • e. hydrogenating the alkali or alkaline earth metal carboxylate salt to form (±)-3-(aminomethyl)-5-methylhexanoic acid, wherein R1 and R2 are the same or different and are hydrogen, C1-C6 alkyl, aryl, benzyl, or C3-C6 cycloalkyl, and
  • f. optionally resolving the obtained (±)-3-(aminomethyl)-5-methylhexanoic acid to obtain (S)-3-(aminomethyl)-5-methylhexanoic acid by standard methods of resolution.
    • In a preferred method decarboxylating and hydrolyzing steps c.) and d.) are combined to form the carboxylate salt.
    The present invention also provides for a method wherein the resolution step comprises:
  • a. combining (±)-3-(aminomethyl)-5-methylhexanoic acid and (S)-mandelic acid in water, an alcohol, or a mixture of water and an alcohol;
  • b. allowing a precipitate to form;
  • c. introducing the precipitate into a polar aprotic solvent or a mixture of polar aprotic solvent and water to form a slurry; and
  • d. collecting the solid from the slurry.
    • The present invention also provides for a method wherein the resolution step comprises:
  • a. combining (±)-3-(aminomethyl)-5-methylhexanoic acid and (R)-mandelic acid in water, an alcohol, or a mixture of water and an alcohol to give the (R,R)-salt;
  • b. crystallizing the salt out of the solution;
  • c. isolating the (S)-3-(aminomethyl)-5-methylhexanoic acid from the solution.
    • Preferred is a resolution method wherein the (±)-3-(aminomethyl)-5-methylhexanoic acid and (S)- or (R)-mandelic acid are combined in a 3% v/v solution of water in isopropyl alcohol.
    Also preferred is a method wherein the (±)-3-(aminomethyl)-5-methylhexanoic acid and (S)- or (R)-mandelic acid are combined in methanol or isopropanol. Preferred polar solvents are dimethylsulfoxide and tetrahydrofuran.
    The invention further provides a compound having the formula
    Figure 00070001
    wherein R1 and R2 are the same or different and are hydrogen, C1-C6 alkyl, aryl, benzyl or C3-C6 cycloalkyl,
    preferably a compound wherein R1 and R2 are ethyl.
    The invention further provides a compound having the formula
    Figure 00070002
    wherein M is hydrogen, an alkali metal, or an alkaline earth metal and R1 is C1-C6 alkyl, aryl, benzyl, or C3-C6 cycloalkyl,
    preferred is a compound wherein M is sodium or potassium.
    Preferred are the mandelic acid salts of 3-(aminomethyl)-5-methylhexanoic acid wherein the mandelic acid is (S)-mandelic acid and the 3-(aminomethyl)-5-methylhexanoic acid is (S)-3-(aminomethyl)-5-methylhexanoic acid or wherein
    the mandelic acid
    is (R)-mandelic acid and the 3-(aminomethyl)-5-methylhexanoic acid is (R)-3-(aminomethyl)-5-methylhexanoic acid or
       wherein the mandelic acid
    is (R)-mandelic acid and the 3-(aminomethyl)-5-methylhexanoic acid is (S)-3-(aminomethyl)-5-methylhexanoic acid or
       wherein the mandelic acid
    is (S)-mandelic acid and the 3-(aminomethyl)-5-methylhexanoic acid is (R)-3-(aminomethyl)-5-methylhexanoic acid.
    DETAILED DESCRIPTION OF THE INVENTION
    In accordance with Scheme I below, the present invention provides an efficient synthesis of racemic isobutyl-GABA and a method for obtaining (S)-isobutyl-GABA from racemic isobutyl-GABA.
    Figure 00090001
    wherein R1 and R2 are the same or different and are hydrogen, C1-C6 alkyl, aryl, benzyl or C3-C6 cycloalkyl; and M is hydrogen, an alkali metal, or an alkaline earth metal.
    Scheme I illustrates a method of making (±)-3-(aminomethyl)-5-methylhexanoic acid (VII or racemic 3-(aminomethyl)-5-methylhexanoic acid), the method comprising condensing isovaleraldehyde (I) with (II) to form (III); reacting (III) with a cyanide source to form (IV); decarboxylating (IV) to form (V); hydrolyzing (V) with an alkali metal or alkaline earth metal hydroxide to form (VI); and hydrogenating (VI) to form (±)-3-(aminomethyl)-5-methylhexanoic acid (VII).
    In a preferred embodiment of the present method, (±)-3-(aminomethyl)-5-methylhexanoic acid can be made by condensing isovaleraldehyde (I) with (II) to form (III); reacting (III) with a cyanide source to form (IV); hydrolyzing and decarboxylating (IV) (step g) to form (VI); and hydrogenating (VI) to form (±)-3-(aminomethyl)-5-methylhexanoic acid (VII).
    Also provided by the present invention is a method for obtaining (S)-3-(aminomethyl)-5-methylhexanoic acid (IX) from (±)-3-(aminomethyl)-5-methylhexanoic acid (VII), the method comprising combining (±)-3-(aminomethyl)-5-methylhexanoic acid and (S)-mandelic acid in water, an alcohol or a mixture of water and an alcohol; allowing a precipitate to form; introducing the precipitate into a polar aprotic solvent, or a polar aprotic solvent and water, to form a slurry; and collecting the solid from the slurry.
    In one step of the present method for making (±)-3-(aminomethyl)-5-methylhexanoic acid, isovaleraldehyde is condensed with
    Figure 00100001
    wherein R1 and R2 are the same or different and are hydrogen C1-C6 alkyl, aryl, benzyl, or C3-C6 cycloalkyl. This type of reaction is known to those skilled in the art as a Knoevenagel Condensation, and the conditions under which a Knoevenagel Condensation can be carried out are well known to those skilled in the art. For example, the condensation can be achieved using a catalytic amount of a base such as di-n-propylamine. Other suitable catalysts are known in the literature. See for example, Tietze L.F., and Beifuss U. in Comprehensive Organic Synthesis, 1991;2:341-394 (Trost B.M., ed.), Pergamon Press. Representative examples of suitable catalysts include pyrrolidine, β-alanine, ammonium acetate, di-isoproplylamine, and di-n-propylamine. These basic catalysts can also be used in combination with an acid such as p-toluene sulfonic acid or acetic acid. A preferred catalyst system in the present method is di-n-propylamine and acetic acid.
    In general, the reaction is run in a refluxing hydrocarbon solvent including, but not limited to, toluene, hexane, heptane, methyl tert-butyl ether or cyclohexane, with the azeotropic removal of water. A preferred solvent is hexane. It is noted that olefin regioisomers can also be formed in the reaction, but are converted to the desired product in a subsequent step in the reaction sequence.
    Representative examples of C1-C6 alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl and hexyl. Representative examples of C3-C6 cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Representative examples of aryl groups include phenyl and substituted phenyl, naphthyl, pridinyl, and the like. The aryl moiety may be substituted with one or more substituents, which can be the same or different. Examples of such groups include C1-C6 alkyl, C1-C6 alkoxy and halogen. Preferably, R1 and R2 are ethyl. In general, the isovaleraldehyde and
    Figure 00110001
    are added to the solvent along with the catalyst, and refluxed with azeotropic removal of water. It is also contemplated that additional catalyst may be added when the rate of azeotropic water collection slows. The progress of the condensation reaction may be monitored by methods well known in the art. A preferred monitoring method is gas chromatography (GC).
    In another step of the present method,
    Figure 00120001
    is reacted with a cyanide source to form
    Figure 00120002
    In general,
    Figure 00120003
    is reacted with a cyanide source in a polar protic solvent such as ethanol, methanol, n-propanol, isopropanol, a mixture of water and alcohols, or polar aprotic solvents such as dimethylsulfoxide (DMSO) or DMSO/water, and then treated with an acid. Examples of suitable cyanide sources include, but are not limited to, hydrogen cyanide, acetone cyanohydrin or an alkali metal or alkaline earth metal cyanide, such as sodium cyanide, potassium cyanide, or magnesium cyanide. The
    Figure 00120004
    in this step may be used in the next step without purification, i.e. in crude form, or it may be purified. Examples of suitable acids are acetic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, benzoic acid, mandelic acid, p-toluenesulfonic acid, and the like.
    The
    Figure 00130001
    can be decarboxylated to form
    Figure 00130002
    in a solvent with a salt. Examples of suitable solvents include mixtures of water and a polar solvent such as ethanol or dimethylsulfoxide (DMSO). Examples of suitable salts include alkali metal and alkaline earth metal halides such as sodium chloride and alkali metal and alkaline earth metal cyanides such as sodium cyanide, magnesium cyanide, and the like.
    The
    Figure 00130003
    can be hydrolyzed with an alkali metal hydroxide or an alkaline earth metal hydroxide to form an alkali or alkaline earth metal carboxylate salt. The alkali or alkaline earth metal hydroxide can be any alkali or alkaline earth metal hydroxide known to those skilled in the art. Examples of suitable alkali metal hydroxides include sodium hydroxide, lithium hydroxide, and potassium hydroxide. Examples of suitable alkaline earth metal hydroxides include calcium hydroxide and magnesium hydroxide. The reaction is usually run in a suitable protic solvent such as water or a mixture of water and a polar protic solvent such as methanol, ethanol, or isopropanol.
    The carboxylate salt can be reduced to give the alkali or alkaline earth metal salt of (±)-3-(aminomethyl)-5-methylhexanoic acid. The carboxylate salt can be protonated with mineral acids or carboxylic acids to give the carboxylic acid and then the nitrile group of the carboxylic acid can be reduced. Conversely, the nitrile group of the carboxylate salt can be reduced, and subsequently protonated to form the carboxylic acid. The salt can be treated with mineral acids or carboxylic acids to give (±)-3-(aminomethyl)-5-methylhexanoic acid. Those skilled in the art are familiar with the reduction of nitrile functional groups. One common method of reducing a nitrile uses a hydrogenation catalyst, such as sponge nickel, in the presence of hydrogen. Other catalysts include palladium, platium, rhodium, cobalt, and nickel. In general, the reaction is run in a solvent system such as a mixture of water and a polar protic solvent.
    The amino carboxylate formed after nitrile reduction can be obtained in the acid form by treating the amino carboxylate with an acid. The mineral acids such as hydrochloric acid can be used. Carboxylic acids, such as acetic acid, can also be used. Preferably, the acid is acetic acid, as a byproduct formed by the reaction is MOAc where M is an alkali metal ion (Na, K, and the like), and OAc is an acetate ion. The salt MOAc is more soluble in aqueous alcoholic solvents than inorganic salts such as sodium chloride, potassium chloride, and the like. Thus, isolation of the product is simplified, and the need for ion exchange treatment to remove excess salts is avoided.
    The cyano acid may also be reduced using a suitable hydrogenation catalyst, such as sponge nickel and hydrogen, in a polar solvent such as methanol, ethanol, or isopropanol in combination with ammonia or a mixture of ammonia and water. Examples of other suitable hydrogenation catalysts include palladium, platium, rhodium, cobalt, and nickel.
    In a preferred method
    Figure 00150001
    is taken to (±)-3-(aminomethyl)-5-methylhexanoic acid without isolation of intermediates. For example,
    Figure 00150002
    can be hydrolyzed using an alkali or alkaline earth metal hydroxide such as potassium hydroxide or sodium hydroxide in an alcohol solvent, which promotes decarboxylation. Further hydrolysis using an alkali or alkaline earth metal hydroxide in water, an alcohol, or a mixture of water and an alcohol, gives carboxylate (VI), which can be reduced with a hydrogenation catalyst followed by treatment with a mineral acid to give racemic 3-(aminomethyl)-5-methylhexanoic acid.
    Racemic 3-(aminomethyl)-5-methylhexanoic acid can be resolved, i.e., the enantiomers separated, by selective crystallization with (S)-mandelic acid. Racemic 3-(aminomethyl)-5-methylhexanoic acid and (S)-mandelic acid can be combined in a solvent such as water or an alcohol or a mixture of water and an alcohol to form a salt. Examples of suitable alcohols include methanol, ethanol, n-propanol, isopropanol, n-butanol, tert-butanol, and the like. In general, the S,S salt precipitates from the solution, and the diastereomer, the R,S salt, stays in solution. Diasteriomeric purity of the S,S salt can be enhanced by further crystallizations. Additional (S)-mandelic acid can be included in the recrystallizations to enhance diastereomeric enrichment. In general, an excess of mandelic acid is used. It is also noted that mandelic acid can be used in combination with another acid in accordance with the "Pope-Peachy" method known in the art.
    Removal of (S)-mandelic acid from the salt to give enriched (S)-3-(aminomethyl)-5-methylhexanoic acid can be done using a polar aprotic solvent such as dimethylsulfoxide or mixtures of dimethylsulfoxide and water or tetrahydrofuran and water, at temperatures typically in the range of about 0°C to about 100°C.
    Trituration to obtain the S-enantiomer has the advantage that it is operationally simple and more economical than traditional acid/base or ion exchange methods.
    Alternatively, (S)-3-(aminomethyl)-5-methyl-hexanoic acid can be obtained by combining (±)-3-(aminomethyl)-5-methylhexanoic acid with (R)-mandelic acid to give the R,R salt which crystallizes out of the solution leaving the solution enriched in (S)-3-(aminomethyl)-5-methylhexanoic acid which can then be isolated from the solution by methods well known to those skilled in the art.
    The (R)-mandelic salt of (S)-3-(aminomethyl)-5-methylhexanoic acid can be isolated as an intermediate, treated with a polar aprotic solvent or mixture of water and a polar aprotic solvent to give the (S)-3-(aminomethyl)-5-methylhexanoic acid.
    It is also possible to obtain (S)-3-(amino methyl)-5-methylhexanoic acid from racemic isobutyl-GABA by standard methods of resolution known to those skilled in the art. It is noted that the isolated solids may be dried at each stage in the resolution or carried on to the next step as solvent-wet solids with comparable results.
    Also provided by the present invention are the novel compounds
    Figure 00170001
    where R1 and R2 are the same or different and are hydrogen, C1-C6 alkyl, aryl, benzyl or C3-C6 cycloalkyl;
    Figure 00170002
    where M is hydrogen, an alkali metal, or an alkaline earth metal;
    Figure 00170003
    where R1 is a defined above; and
    Figure 00170004
    It is also contemplated that the compounds of the present method can be found or isolated in the form of hydrates or solvates, which are considered to fall within the scope of the present invention.
    The examples below are intended to illustrate specific embodiments of the invention.
    EXAMPLES Preparation of 2-Carboxyethyl-5-methylhex-2-enoic acid, ethyl ester
    Figure 00180001
    Isovaleraldehyde (361.6 kg, 4198.3 mol) was combined with diethyl malonate (640.8 kg, 4000.7 mol), hexane (1000 L), di-n-propylamine (20.0 kg, 197.6 mol), and glacial acetic acid (24.0 kg, 399.7 mol) in a 4000 L vessel. The mixture was heated to reflux (jacket temperature set at 90°C) with continuous removal of water until the rate of water collection slowed significantly (69.4 kg water was collected versus 72.0 kg expected by theory).
    At this point, the mixture was cooled to below 60°C and a second catalyst addition was carried out by charging di-n-propylamine (20.0 kg, 197.6 mol), and glacial acetic acid (24.0 kg, 399.7 mol) to the mixture. (The second catalyst addition is optional, but helps to bring the reaction to completion faster. This modification shows improved purity profiles and yields in some cases versus a single catalyst charge.)
    The mixture was heated to reflux (jacket temperature set at 90°C) with continuous removal of water for an additional 22.5 hours or until the reaction is judged complete by GC assay (>90% combined product and isomer). The mixture was brought to <40°C and was washed with water (2 × 800 L). The organic layer was concentrated by atmospheric pressure distillation until most of the hexane was removed. The remaining oil was further concentrated by vacuum distillation at 40°C for 2-18 hours.
    The product was obtained as a colorless liquid (810.0 kg, 88.7% yield) and contained a mixture of olefin isomers (both of which are converted to the same product in the next synthetic step). The major isomer is 2-carboxyethyl-5-methylhex-2-enoic acid, ethyl ester; the minor isomer (typically 10-13% by GC) is believed to be 2-carboxyethyl-5-methylhex-3-enoic acid, ethyl ester.
    Description: Colorless to yellow liquid
    GC Assay: 74-76% 2-carboxyethyl-5-methylhex-2-enoic acid ethyl ester; 10-13% 2-carboxyethyl-5-methylhex-3-enoic acid ethyl ester; 87-88% Total of both isomers. 1H NMR, Note: Chemical shifts and multiplicities are reported as observed for a sample of the mixture prepared by the process described above. The observed integration results are slightly different than would be expected for pure 2-carboxyethyl-5-methylhex-2-enoic acid ethyl ester due to the presence of two olefin isomers. Thus, the integration has been reported as would be expected for a pure sample of 2-carboxyethyl-5-methylhex-2-enoic acid ethyl ester.
    1H NMR (CDCl3, 200 MHz): δ 0.91-1.02 (m, 6H), 1.23-1.37 (m, 6H), 1.78-1.85 (m, 1H), 2.16-2.23 (m, 2H) 4.19-4.36 (m, 4H), 7.02 (t, 1H, J = 7.9 Hz).
    Boiling Point: Purified samples can be obtained by vacuum distillation: 101-104°C at 1.1-1.2 mm Hg; or 132°C at 5 mm Hg.
    Preparation of 2-Carboxyethyl-3-cyano-5-methylhexanoic acid, ethyl ester
    Figure 00190001
    2-Carboxyethyl-5-methylhex-2-enoic acid ethyl ester (692.7 kg, 3034 mol) was charged to a 4000 L vessel containing potassium cyanide (172.6 kg, 2650 mol) and 2B ethanol (700 kg). The resulting slurry was stirred at 25-40°C for at least 18 hours or until in-process HPLC assay indicated less than 5% 2-carboxyethyl-5-methylhex-2-enoic acid, ethyl ester (typically 22-24 hours). Hexane (890 L) was charged to the slurry. Glacial acetic acid (175 kg, 2914 mol) was slowly added keeping the temperature <35°C. To the resulting thick slurry was added water (820 L) with stirring. The layers were separated. The aqueous layer was extracted with hexane (1 × 890 L). The organic layers were combined and washed with water (1 × 420 L). The water layer was separated and the remaining organic solution was distilled at atmospheric pressure until most of the hexane was removed. The oil was then further concentrated by vacuum distillation at 40°C for 2-19 hours. The product was obtained as a liquid (752.6 kg, 93.8%).
    Description: Colorless to orange liquid
    HPLC Assay: 83-86% 2-carboxyethyl-3-cyano-5-methylhexanoic acid, ethyl ester 1H NMR (DMSO-d6, 200 MHz): δ 0.92 (t, 6H, J = 6.1 Hz), 1.15-1.21 (m, 6H), 1.23-1.36 (m, 1H), 1.54-1.68 (m, 2H), 3.25-3.33 (m, 1H), 3.97 (d, 1H, J = 6.5 Hz), 4.10-4.25 (m, 4H).
    Preparation of 3-Cyano-5-methylhexanoic acid, ethyl ester
    Figure 00200001
    An 800 L still was charged with sodium chloride (21 kg, 359 mol), 2-carboxyethyl-3-cyano-5-methylhexanoic acid, ethyl ester (80.0 kg, 313 mol), dimethylsulfoxide (238 kg), and water (10.8 kg, 600 mol). The mixture was heated to 137-148°C for 8.5 hours. The mixture was cooled to below 50°C, and treated with methyl tert-butyl ether (125 kg). The mixture was cooled to 0-10°C, and treated with water (160 L) in portions to maintain the temperature below 40°C. After stirring for 15-30 minutes, the phases were separated. The aqueous phase was extracted with methyl tert-butyl ether (125 kg). The organic extracts were combined with a vessel rinse (25 kg methyl tert-butyl ether) and was extracted with water (110 L). The water phase was discarded. The methyl tert-butyl ether phase was concentrated by atmospheric pressure distillation to a batch temperature of about 65°C. The batch was cooled to 30-40°C and further concentrated by vacuum distillation until the solvent content was acceptable (<5% methyl tert-butyl ether by area %GC analysis). The product was obtained as a brown oil
    (51.3 kg, 85.7%).
    Description: Colorless to dark brown oil GC Assay (area %): 86.20%
    Boiling Point: Purified samples can be obtained by vacuum distillation: 99-103°C at 1.3-1.5 mm Hg
    1H NMR (CDCl3, 200 MHz): δ 0.88-0.99 (m, 6H), 1.19-1.40 (m, 4H), 1.57-1.69 (m, 1H), 1.72-1.84 (m, 1H), 2.53 (dd, 1H, J = 6.8 Hz, J = 16.6 Hz), 2.70 (dd, 1H, J = 7.4 Hz, J = 16.5 Hz), 2.99-3.10 (m, 1H), 4.21 (q, 2H, J = 7.1 Hz).
    Preparation Of Racemic 3-(Aminomethyl)-5-methylhexanoic acid
    Figure 00220001
    An 800 L still was charged with 3-cyano-5-methyl hexanoic acid, ethyl ester (50.1 kg, 273 mol) and ethyl alcohol 2B (53 kg). A solution of potassium hydroxide (17.8 kg, 317 mol) in water (56 L) was added controlling the addition rate to maintain the batch temperature below 25°C. The mixture was stirred at 20-25°C for about 1.5 hours.
    The batch was transferred to a hydrogenator containing sponge nickel (15.0 kg, 50% water wet), followed by a rinse of ethyl alcohol 2B (27 kg). The mixture was treated with hydrogen at about 50 psi for about 19 hours (hydrogen uptake stopped).
    The nickel was removed by filtration and the filter cake was rinsed with a mixture of 39 kg ethyl alcohol 2B and 111 L water. To the filtrate was added glacial acetic acid (22.8 kg, 380 mol) maintaining the batch temperature less than 40°C. The batch was heated to 70-75°C to dissolve the solids. The batch was slowly cooled to 0-5°C to crystallize the product.
    The solid was collected on a centrifuge and rinsed with 160 L isopropyl alcohol that was previously cooled to 0-5°C.
    The damp solid was dried in a vacuum tray drier under vacuum at 35-45°C (28 hours) to give 31.4 kg (75.1%) of racemic 3-aminomethyl-5-methylhexanoic acid.
    The product was characterized by HPLC and NMR. The water content for this product was 9.51% by weight (Karl Fischer). The product may contain a variable amount of water ranging from nearly anhydrous up to about 10.2% (monohydrate).
    Description: White to off-white solid HPLC Assay: 102.05% w/w
    Melting Point: 166.0-167.5°C
    1H NMR (D2O, 200 MHz): δ 0.86-0.90 (m, 6H), 1.21 (t, 2H, J = 7.0 Hz), 1.62-1.69 (m, 1H), 2.12-2.35 (m, 3H), 2.94-3.00 (m, 2H).
    Preparation of Racemic 3-(Aminomethyl)-5-methylhexanoic acid
    Figure 00230001
    A 2000 L still was charged with 2-carboxyethyl-3-cyano-5-methyl hexanoic acid, ethyl ester (286 kg, 1120 mol) and methyl alcohol (100 L). A solution of potassium hydroxide (60.8 kg, 1046 mol) in methyl alcohol (260 L) was added controlling the addition rate so as to keep the batch temperature about 20-35°C. A rinse of 40 L methyl alcohol was added to the batch and the mixture was heated to reflux for 4-5 hours. The batch was cooled to 25-30°C and a solution of potassium hydroxide (121.6 kg, 2167 mol) in water (200 L) was added maintaining the batch temperature below 50°C.
    The batch was concentrated by vacuum distillation to about 580 L volume. Water (100 L) was added and the distillation continued to a volume of about 510 L.
    The batch was transferred to an 800 L hydrogenator containing 44.8 kg sponge nickel (50% water wet), along with a mixture of 20 L water and 30 kg ethyl alcohol 2B as a rinse. The mixture was treated with hydrogen at about 50 psi for about 18-19 hours (hydrogen uptake stopped).
    To the batch was added 58 kg ethyl alcohol 2B and the nickel was removed by filtration. The filter cake was rinsed with a mixture of 100 kg ethyl alcohol 2B and 270 L water.
    The filtrate was transferred to a 2000 L still containing 222 kg (3697 mol) glacial acetic acid at 50-60°C controlling the addition rate to control gas evolution and to maintain the temperature at 50-60°C. A rinse of 40 L water was added to the batch and the temperature increased to 70-75°C to dissolve the solids. The batch was slowly cooled to 0-5°C to crystallize the product.
    The solid was collected on a centrifuge and rinsed with 570 L isopropyl alcohol.
    The damp solid was dried in a vacuum tray drier under vacuum at 35-45°C (22 hours) to give 108.1 kg (72.7%) of racemic 3-aminomethyl-5-methylhexanoic acid. The product was characterized by HPLC and NMR. The product may contain variable amounts of water ranging from nearly anhydrous (1.68% by weight in this example) up to about 10.2% (monohydrate).
    Description: White to off-white solid HPLC Assay: 99.67% w/w
    Melting Point: 166.0-167.5°C
    1H NMR (D2O, 200 MHz): δ 0.88-0.92 (m, 6H), 1.23 (t, 2H, J = 6.9 Hz), 1.64-1.70 (m, 1H), 2.13-2.37 (m, 3H), 2.96-3.01 (m, 2H).
    Resolution of Racemic 3-(Aminomethyl)-5-methylhexanoic acid
    Figure 00250001
    A solution of 3% v/v water in isopropyl alcohol was prepared by mixing water (9 kg) and isopropyl alcohol (291 L) in a 400 L reactor. This was repeated. The solvent was stored in plastic drums and used as necessary (described below).
    A 400 L still was charged with racemic 3-aminomethyl-5-methylhexanoic acid (29.7 kg, 168 mol), S-(+)-mandelic acid (39.3 kg, 258 mol), and 3% v/v water/isopropyl alcohol solution (244 kg) prepared earlier. The mixture was heated to dissolve the solids (about 65-80°C), cooled, and seeded with S,S-salt to crystallize the mixture of diastereomeric mandelate salts enriched in the S,S-isomer. The solid was collected on a centrifuge and rinsed with 3% water/isopropanol (21.5 kg). (S/R isomer ratio: 93.7% S: 6.3% R. The solid may optionally be dried at this stage or carried on as a solvent-wet solid).
    The damp salt was charged to a 400 L still along with (S)-(+)-mandelic acid (5.8 kg, 38 mol) and 3% water/isopropyl alcohol (121 kg). The mixture was heated to dissolve the solids (about 65-80°C), cooled, and seeded if necessary, with S,S-salt to crystallize the mixture of diastereomeric mandelate salts further enriched in the S,S-isomer. The solid was collected on a centrifuge and rinsed with 3% water/isopropyl alcohol (33.3 kg). The solid may optionally be dried at this stage or carried on as a solvent-wet solid (S/R isomer ratio: 99.5% S:0.5% R). The dried S,S-salt typically has the following characteristics: Description: White to off-white solid; mp 133-134°C;
    1H NMR (D2O, 200 MHz): δ 0.87-0.92 (m, 6H), 1.24 (t, J = 7.2 Hz, 2H), 1.55-1.76 (m, 1H), 2.11-2.52 (m, 3H), 3.00 (d, J = 6.2 Hz, 2H), 5.07 (s, 1H), 7.43 (s, 5H).
    The damp salt was transferred to a 400 L reactor with tetrahydrofuran (195 L) and water (10 kg). The mixture was warmed to 60-65°C, and cooled to 0-5°C. The crude (S)-isobutyl GABA solid was collected on a centrifuge and rinsed with a mixture of tetrahydrofuran (28 L)/water (1 kg). The solid may optionally be dried at this stage or carried on as a solvent-wet solid (S/R isomer ratio: 100% S:<0.05% R isomer (not detected)).
    The damp solid was transferred to a 200 L still with isopropyl alcohol (113 L) and water (38 kg). The mixture was heated to dissolve the solids (about 75-80°C), filtered while hot, and cooled to 0-5°C to crystallize the (S)-isobutyl GABA. The solid was collected on a centrifuge and rinsed with 25 L isopropyl alcohol. The damp solid was dried in a vacuum tray drier under vacuum at 35-45°C to give 7.4 kg (S)-isobutyl GABA.
    Description: White to off-white solid HPLC Assay: 99.4% w/w
    Chiral Purity (HPLC): 100% S; R-isomer not detected (limit of detection 0.05%)
    Melting Point: 177-179°C (decomposes)
    1H NMR (D2O, 200 MHz): δ 0.88-0.92 (m, 6H), 1.23 (t, 2H, J = 6.9 Hz), 1.64-1.70 (m, 1H), 2.13-2.32 (m, 3H), 2.96-3.01 (m, 2H).
    Resolution of Racemic 3-(Aminomethyl)-5-methylhexanoic acid
    A solution of 3% v/v water in isopropyl alcohol was prepared by mixing water (5.7 kg) and isopropyl alcohol (184 L) in a 400 L reactor. The solvent was stored in plastic drums and used as necessary (described below).
    A 2000 L reactor was charged with racemic 3-aminomethyl-5-methylhexanoic acid (117.6 kg, 673 mol). A 2000 L still was charged with water (36 L), S-(+)-mandelic acid (153.0 kg, 1006 mol), and isopropyl alcohol (1170 L). The mandelic acid mixture was heated to 55-65°C and the resulting solution was transferred to the reactor containing racemic 3-aminomethyl-5-methylhexanoic acid. The batch was heated to 50-65°C just long enough to dissolve the solids.
    [Note: Batch heating and temperature are kept to the minimum necessary to dissolve solids in order to minimize acid catalyzed decomposition of racemic 3-aminomethyl-5-methylhexanoic acid to the corresponding lactam. This decomposition is undesired because it lowers product yield.]
    The mixture was cooled to 40-45°C, seeded with S,S-salt (20 g), and further cooled to 20-25°C to crystallize the mixture of diastereomeric mandelate salts enriched in the S,S-isomer. After maintaining the temperature at 20-25°C for at least 12 hours, the solid was collected on a centrifuge and rinsed with 3% water/isopropanol solution (100 kg) prepared earlier.
    [Note: S/R isomer ratio: 92.5% S:7.5% R. The solid may optionally be dried at this stage or carried on as a solvent-wet solid.]
    The solvent-wet S,S-salt was charged to an 800 L reactor. An 800 L still was charged with water (14.4 kg), (S)-(+)-mandelic acid (23.0 kg, 151 mol), and isopropyl alcohol (468 L). The mandelic acid mixture was heated to 65-70°C, and the resulting solution was transferred to the reactor containing the solvent-wet salt. The batch was heated to 60-70°C just long enough to dissolve the solids or, if solids do not dissolve, until batch temperature reached 70°C.
    [Note: Batch heating and temperature are kept to the minimum necessary either to dissolve solids or to reach 70°C, in order to minimize acid catalyzed decomposition to the corresponding lactam. This decomposition is undesired because it lowers product yield.]
    The mixture was cooled to 50-55°C. Seeding with S,S-salt at this temperature range is optional but is typically not needed to induce crystallization or further diastereomeric enrichment. The batch was further cooled to 0-5°C to crystallize the mixture of diastereomeric mandelate salts enriched in the S,S-isomer. After maintaining the temperature at 0-5°C for at least 12 hours, the solid was collected on a centrifuge and rinsed with 3% water/isopropanol solution (100 kg) prepared earlier.
    [Note: S/R isomer ratio: 98.6% S:1.4% R. The solid may optionally be dried at this stage or carried on as a solvent-wet solid. The dried S,S-salt typically has the following characteristics: Description: White to off-white solid; mp 133-134°C [36832 × 88]; 1H NMR (D2O, 200 MHz): δ 0.87-0.92 (m, 6H), 1.24 (t, J = 7.2 Hz, 2H), 1.55-1.76 (m, 1H), 2.11-2.52 (m, 3H), 3.00 (d, J = 6.2 Hz, 2H), 5.07 (s, 1H), 7.43 (s, 5H).]
    An 800 L reactor was charged with water (31 L), the solvent-wet S,S-salt, and tetrahydrofuran (595 L). The mixture was warmed to 50-55°C, and cooled to 0-5°C. After maintaining the temperature at 0-5°C for at least 12 hours, the solid was collected on a centrifuge and rinsed with tetrahydrofuran (50 L) and then with isopropyl alcohol (50 L).
    [Note: S/R isomer ratio: 99.94% S:0.06% R. The solid may optionally be dried at this stage or carried on as a solvent-wet solid.]
    An 800 L reactor was charged with water (155 L), the solvent-wet CI-1008, and isopropyl alcohol (465 L). The mixture was heated to dissolve the solids (about 75-80°C), filtered while hot, cooled to 40-45°C, seeded with CI-1008 (10 g), and further cooled to 0°C to -5°C to crystallize the CI-1008. The solid was collected on a centrifuge and rinsed with isopropyl alcohol (50 L). The damp solid was dried in a vacuum tray drier under vacuum at 35-45°C to give 32.4 kg CI-1008 (60.4% yield).
    Description: White to off-white solid HPLC Assay: 100.32% w/w
    Chiral Purity (HPLC): 100% S; R-isomer not detected (limit of detection 0.05%)
    1H NMR (D2O, 200 MHz): δ 0.86-0.90 (m, 6H), 1.21 (t, 2H, J = 7.1 Hz), 1.62-1.65 (m, 1H), 2.15-2.35 (m, 3H), 2.94-2.99 (m, 2H). [CD 2586] Melting Point: 177-179°C (decomposes)

    Claims (22)

    1. A method of making (±)-3-(aminomethyl)-5-methylhexanoic acid and its S-form, (S)-3-(aminomethyl)-5-methylhexanoic acid, the method comprising:
      a. condensing isovaleraldehyde with
      Figure 00300001
      to form primarily
      Figure 00300002
      b. reacting the
      Figure 00300003
      with a cyanide source to form
      Figure 00300004
      c. decarboxylating the
      Figure 00310001
      to form
      Figure 00310002
      d. hydrolyzing the
      Figure 00310003
      with an alkali or alkaline earth metal hydroxide to form an alkali or alkaline earth metal carboxylate salt;
      e. hydrogenating the alkali or alkaline earth metal carboxylate salt to form (±)-3-(aminomethyl)-5-methylhexanoic acid, wherein R1 and R2 are the same or different and are hydrogen, C1-C6 alkyl, aryl, benzyl, or C3-C6 cycloalkyl, and
      f. optionally resolving the obtained (±)-3-(aminomethyl)-5-methylhexanoic acid to obtain (S)-3-(aminomethyl)-5-methylhexanoic acid by standard methods of resolution.
    2. A method according to Claim 1 wherein decarboxylating and hydrolyzing steps c.) and d.) are combined to form the carboxylate salt.
    3. The method of Claim 1 or 2 wherein R1 and R2 of
      Figure 00320001
      are ethyl.
    4. The method of Claim 1 or 2 wherein the isovaleraldehyde and
      Figure 00320002
      are condensed in the presence of di-n-propylamine and acetic acid.
    5. The method of Claim 1 or 2 wherein the cyanide source is potassium cyanide.
    6. The method of Claim 1 or 2 wherein the alkali metalhydroxide is potassium hydroxide.
    7. The method of Claim 1 or 2 wherein the hydrogenation is carried out in the presence of hydrogen and sponge nickel.
    8. The method of Claim 1 or 2 wherein the resolution step comprises:
      a. combining (±)-3-(aminomethyl)-5-methylhexanoic acid and (S)-mandelic acid in water, an alcohol, or a mixture of water and an alcohol;
      b. allowing a precipitate to form;
      c. introducing the precipitate into a polar aprotic solvent or a mixture of polar aprotic solvent and water to form a slurry; and
      d. collecting the solid from the slurry.
    9. The method of Claim 1 or 2 wherein the resolution step comprises:
      a. combining (±)-3-(aminomethyl)-5-methylhexanoic acid and (R)-mandelic acid in water, an alcohol, or a mixture of water and an alcohol to give the (R,R)-salt;
      b. crystallizing the salt out of the solution;
      c. isolating the (S)-3-(aminomethyl)-5-methylhexanoic acid from the solution.
    10. The method of Claim 8 or 9 wherein the (±)-3-(aminomethyl)-5-methylhexanoic acid and (S)- or (R)-mandelic acid are combined in a 3% v/v solution of water in isopropyl alcohol.
    11. The method of Claim 8 or 9 wherein the (±)-3-(aminomethyl)-5-methylhexanoic acid and (S)- or (R)-mandelic acid are combined in methanol and isopropanol.
    12. The method of Claim 8 or 9 wherein the polar aprotic solvent is dimethylsulfoxide.
    13. The method of Claim 8 or 9 wherein the polar aprotic solvent is tetrahydrofuran.
    14. A compound having the formula
      Figure 00340001
      wherein R1 and R2 are the same or different and are hydrogen, C1-C6 alkyl, aryl, benzyl or C3-C6 cycloalkyl.
    15. The compound of Claim 14 wherein R1 and R2 are ethyl.
    16. The compound having the formula
      Figure 00340002
      wherein M is hydrogen, an alkali metal, or an alkaline earth metal and R1 is C1-C6 alkyl, aryl, benzyl, or C3-C6 cycloalkyl.
    17. The compound of Claim 16 wherein M is sodium or potassium.
    18. The mandelic acid salts of (±)3-(aminomethyl)-5-methylhexanoic acid.
    19. The compound of Claim 18 wherein the mandelic acid is (S)-mandelic acid and the 3-(aminomethyl)-5-methylhexanoic acid is (S)-3-(aminomethyl)-5-methylhexanoic acid.
    20. The compound of Claim 18 wherein the mandelic acid is (R)-mandelic acid and the 3-(aminomethyl)-5-methylhexanoic acid is (R)-3-(aminomethyl)-5-methylhexanoic acid.
    21. The compound of Claim 18 wherein the mandelic acid is (R)-mandelic acid and the 3-(aminomethyl)-5-methylhexanoic acid is (S)-3-(aminomethyl)-5-methylhexanoic acid.
    22. The compound of Claim 18 wherein the mandelic acid is (S)-mandelic acid and the 3-(aminomethyl)-5-methylhexanoic acid is (R)-3-(aminomethyl)-5-methylhexanoic acid.
    EP96914618A 1995-06-07 1996-05-13 Method of making 3-(aminomethyl)-5-methylhexanoic acid Expired - Lifetime EP0830338B1 (en)

    Priority Applications (1)

    Application Number Priority Date Filing Date Title
    SI9630390T SI0830338T1 (en) 1995-06-07 1996-05-13 Method of making 3-(aminomethyl)-5-methylhexanoic acid

    Applications Claiming Priority (3)

    Application Number Priority Date Filing Date Title
    US08/474,874 US5637767A (en) 1995-06-07 1995-06-07 Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
    US474874 1995-06-07
    PCT/US1996/006819 WO1996040617A1 (en) 1995-06-07 1996-05-13 Method of making (s)-3-(aminomethyl)-5-methylhexanoic acid

    Publications (2)

    Publication Number Publication Date
    EP0830338A1 EP0830338A1 (en) 1998-03-25
    EP0830338B1 true EP0830338B1 (en) 2001-12-12

    Family

    ID=23885291

    Family Applications (1)

    Application Number Title Priority Date Filing Date
    EP96914618A Expired - Lifetime EP0830338B1 (en) 1995-06-07 1996-05-13 Method of making 3-(aminomethyl)-5-methylhexanoic acid

    Country Status (18)

    Country Link
    US (4) US5637767A (en)
    EP (1) EP0830338B1 (en)
    JP (1) JP3874306B2 (en)
    AT (1) ATE210628T1 (en)
    CA (1) CA2219150C (en)
    CZ (2) CZ291147B6 (en)
    DE (1) DE69617948T2 (en)
    DK (1) DK0830338T3 (en)
    EE (1) EE04053B1 (en)
    ES (1) ES2170231T3 (en)
    GE (1) GEP19991870B (en)
    HU (2) HU229957B1 (en)
    NZ (2) NZ501628A (en)
    PL (3) PL185425B1 (en)
    PT (1) PT830338E (en)
    SI (1) SI0830338T1 (en)
    SK (2) SK283507B6 (en)
    WO (1) WO1996040617A1 (en)

    Cited By (2)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    CN105348125A (en) * 2015-11-26 2016-02-24 太仓运通生物化工有限公司 Method for synthesizing Pregabalin by taking isovaleraldehyde as raw material
    CN111333529A (en) * 2018-12-19 2020-06-26 北京万全德众医药生物技术有限公司 Preparation method of pregabalin

    Families Citing this family (69)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    US5858736A (en) * 1996-05-17 1999-01-12 E. I. Du Pont De Nemours And Company Preparation of lactams from aliphatic α,ω-dinitriles
    KR100491282B1 (en) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 Isobutylgaba and Its Derivatives for the Treatment of Pain
    US6194459B1 (en) 1997-08-19 2001-02-27 Warner-Lambert Company Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotors stimulants
    MXPA01012319A (en) * 1999-06-10 2002-07-22 Warner Lambert Co Mono- and disubstituted 3-propyl gamma-aminobutyric acids.
    SI1250311T1 (en) * 2000-01-27 2004-10-31 Warner-Lambert Company Asymmetric synthesis of pregabalin
    GB2368579A (en) * 2000-10-31 2002-05-08 Parke Davis & Co Ltd Azole pharmaceutical agents
    US7169812B2 (en) * 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
    EP1543831A1 (en) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Pregabalin composition
    NZ549004A (en) * 2004-03-12 2009-04-30 Warner Lambert Co C1-symmetric bisphosphine ligands and their use in the asymmetric synthesis of pregabalin
    UA82292C2 (en) * 2004-04-14 2008-03-25 Пфайзер Продактс Инк. A method for stereoselective byconversion of aliphatic dinitriles into cyanocarboxylic acids (variants)
    EP1831154B1 (en) * 2004-06-21 2010-01-13 Warner-Lambert Company LLC Preparation of pregabalin and related compounds
    US7417165B2 (en) * 2005-04-06 2008-08-26 Teva Pharmaceutical Industries Ltd. Crystalline forms of pregabalin
    EP1768950A2 (en) * 2005-04-11 2007-04-04 Teva Pharmaceutical Industries Ltd. Process for making (s)-pregabalin
    US7488846B2 (en) * 2005-04-11 2009-02-10 Teva Pharmaceuical Industries Ltd. Pregabalin free of lactam and a process for preparation thereof
    ATE486841T1 (en) * 2005-05-10 2010-11-15 Teva Pharma METHOD FOR PRODUCING PREGABALIN AND SALTS THEREOF
    MX2007014129A (en) * 2005-05-10 2008-01-11 Teva Pharma Optical resolution of 3-carbamoylmethyl-5-methyl hexanoic acid.
    WO2006121557A1 (en) * 2005-05-10 2006-11-16 Teva Pharmaceutical Industries Ltd. Pregabalin free of lactam and a process for preparation thereof
    WO2006122255A1 (en) * 2005-05-10 2006-11-16 Teva Pharmaceutical Industries Ltd. Pregabalin free of isobutylglutaric acid and a process for preparation thereof
    ES2398579T3 (en) * 2005-09-19 2013-03-20 Teva Pharmaceutical Industries Ltd An asymmetric synthesis of (S) - (+) - 3- (aminomethyl) -5-methylhexanoic acid
    NL2000281C2 (en) 2005-11-02 2007-08-07 Pfizer Prod Inc Solid pharmaceutical compositions containing pregabalin.
    US20070259917A1 (en) * 2006-04-24 2007-11-08 Kansal Vinod K Processes for the synthesis of 3-isobutylglutaric acid
    KR20080027880A (en) * 2006-05-24 2008-03-28 테바 파마슈티컬 인더스트리즈 리미티드 Processes for the preparation of r-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof
    KR20080036060A (en) 2006-05-31 2008-04-24 테바 파마슈티컬 인더스트리즈 리미티드 The use of enzymatic resolution for the preparation of intermediates of pregabalin
    EP1912931A2 (en) * 2006-05-31 2008-04-23 Teva Pharmaceutical Industries Ltd. Preparation of (s)-pregabalin-nitrile
    AU2007274034B2 (en) * 2006-07-12 2012-11-15 Generics [Uk] Limited Process of preparing a gamma-amino acid
    WO2008062460A2 (en) * 2006-10-06 2008-05-29 Cadila Healthcare Limited Crystalline forms of pregabalin
    EP2021318A2 (en) * 2007-03-22 2009-02-11 Teva Pharmaceutical Industries Ltd. Synthesis of (s)-(+)-3-(aminomethyl)-5-methyl hexanoic acid
    WO2008138874A1 (en) * 2007-05-09 2008-11-20 Chemo Ibérica, S.A. Process for preparing (s)-pregabalin by optical resolution of racemic pregabalin
    EP1992609A1 (en) * 2007-05-14 2008-11-19 Dipharma Francis S.r.l. A process for the preparation of a (S)(+)-3-(aminomethyl)-5-methylhexanoic acid
    EP2170813A4 (en) * 2007-06-25 2012-05-16 Reddy Manne Satyanarayana A novel process for the preparation of pregabalin
    WO2009044409A2 (en) * 2007-10-01 2009-04-09 Natco Pharma Limited Novel resolution process for pregabalin
    KR20090101462A (en) * 2007-10-03 2009-09-28 테바 파마슈티컬 인더스트리즈 리미티드 Pregabalin-4-eliminate, pregabalin-5-eliminate, their use as reference marker and standard, and method to produce pregabalin containing low levels thereof
    ITMI20072262A1 (en) * 2007-12-03 2009-06-04 Dipharma Francis Srl PROCEDURE FOR THE PREPARATION OF ACID (S) (+) - 3- (AMINOMETHYL) -5-METHYLESANOIC
    WO2009087674A2 (en) * 2007-12-18 2009-07-16 Watson Pharma Private Limited Improved process for the preparation of (s)-pregabalin
    CN101965328A (en) * 2007-12-26 2011-02-02 基因里克斯(英国)有限公司 Process to pregabalin
    KR101489267B1 (en) 2007-12-27 2015-02-04 도오레 화인케미칼 가부시키가이샤 Optically active 3-aminopyrrolidine salt, process for production thereof, and method for optical resolution of 3-aminopyrrolidine
    WO2009082861A1 (en) * 2008-01-02 2009-07-09 Zhejiang Jiuzhou Pharmaceutical Co., Ltd. New resolution process of (s)-3-aminomethyl-5-methylhexanoic acid
    WO2009125427A2 (en) * 2008-02-18 2009-10-15 Matrix Laboratories Limited Process for preparing (s)-3-(aminomethyl)-5-methylhexanoic acid
    JP2011516459A (en) * 2008-04-04 2011-05-26 ジェネリクス・（ユーケー）・リミテッド New method
    EP2110372A1 (en) 2008-04-16 2009-10-21 Chemo Ibérica, S.A. Intermediates for the preparation of Pregabalin and process for their preparation
    CN101585778B (en) * 2008-05-19 2014-08-13 上海臣邦医药科技有限公司 Lyrica preparation method
    MX2010012698A (en) * 2008-05-21 2011-03-15 Sandoz Ag Process for the stereoselective enzymatic hydrolysis of 5-methyl-3-nitromethyl-hexanoic acid ester.
    CN102112436A (en) * 2008-06-03 2011-06-29 基因里克斯(英国)有限公司 Novel and efficient method for synthesis of amino acid
    US20100087525A1 (en) * 2008-06-23 2010-04-08 Lilach Hedvati Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester
    WO2010061403A2 (en) * 2008-11-26 2010-06-03 Ind-Swift Laboratories Limited Process to prepare highly pure (s)-pregabalin
    WO2010070593A2 (en) 2008-12-19 2010-06-24 Pfizer Ireland Pharmaceuticals Malonate esters
    IT1394292B1 (en) 2009-05-07 2012-06-06 Dipharma Francis Srl PROCEDURE FOR THE SYNTHESIS OF PREGABALINA
    ES2362913B1 (en) 2009-12-24 2012-05-24 Moehs Iberica S.L. NEW METHOD FOR THE PREPARATION OF (S) -PREGABALINA.
    HUP1000186A2 (en) 2010-04-08 2011-10-28 Richter Gedeon Nyrt Novel industrial process of preparing (s)-(+) pregabalin
    WO2011141923A2 (en) 2010-05-14 2011-11-17 Lupin Limited Improved synthesis of optically pure (s) - 3-cyano-5-methyl-hexanoic acid alkyl ester, an intermediate of (s)- pregabalin
    US8212072B2 (en) 2010-08-13 2012-07-03 Divi's Laboratories, Ltd. Process for the preparation of pregabalin
    WO2012025861A1 (en) 2010-08-23 2012-03-01 Pfizer Manufacturing Ireland Process for the preparation of ( s ) - 3 - cyano - 5 - methylhexanoic acid derivatives adn of pregabalin
    EP2700645A4 (en) 2011-04-20 2014-09-24 Kemphys Ltd Silicon-containing carboxylic acid derivative
    EP2527319A1 (en) 2011-05-24 2012-11-28 Laboratorios Del. Dr. Esteve, S.A. Crystalline forms of pregabalin and co-formers in the treatment of pain
    EP2910560B1 (en) 2012-10-18 2017-09-06 Kemphys Ltd. Silicon-containing carboxylic acid derivative
    CA2888877C (en) 2012-11-07 2021-07-27 Hikal Limited A process for the preparation of pregabalin
    CN103980144B (en) * 2014-05-16 2018-08-17 浙江华海药业股份有限公司 A kind of using method of pregabalin intermediate mother liquor
    US9745249B2 (en) 2014-06-12 2017-08-29 Siegfried Ltd. Method for the preparation of beta-substituted gamma-amino carboxylic acids
    CN104086439B (en) * 2014-06-30 2018-11-16 浙江华海药业股份有限公司 A kind of recovery method of pregabalin intermediate resolving agent (R)-(+)-α-phenylethylamine
    WO2016075082A1 (en) 2014-11-10 2016-05-19 Sandoz Ag Stereoselective reductive amination of alpha-chiral aldehydes using omega-transaminases for the synthesis of precursors of pregabalin and brivaracetam
    CN104649919B (en) * 2015-02-10 2021-02-12 浙江华海药业股份有限公司 Preparation method of small-particle pregabalin
    JP2018520112A (en) 2015-05-26 2018-07-26 オディディ，イサ Controlled sustained release pregabalin
    CN105175276A (en) * 2015-07-25 2015-12-23 安徽东凯生物科技有限公司 Synthetic method for optically pure(R)-3-carbamyl methyl-5-methyl caproic acid
    CN105061234A (en) * 2015-08-18 2015-11-18 太仓运通生物化工有限公司 Preparation method for pregabalin
    CN105085290A (en) * 2015-08-18 2015-11-25 太仓运通生物化工有限公司 Method for synthesizing pregabalin
    CN109942446B (en) * 2019-04-17 2021-09-07 黄冈鲁班药业股份有限公司 Preparation method of pregabalin
    EP4230199A4 (en) 2020-12-04 2024-07-31 Laboratorios Silanes S A De C V Stable coated solid pharmaceutical composition of an opioid analgesic and an anti-epileptic for pain
    CN112939809A (en) * 2020-12-30 2021-06-11 江苏恒沛药物科技有限公司 Preparation method of 1-cyano-3-methyl diethyl butylmalonate
    CN116041214A (en) * 2022-11-15 2023-05-02 奥锐特药业股份有限公司 Preparation method and application of pregabalin intermediate

    Family Cites Families (14)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    US2516307A (en) * 1949-01-06 1950-07-25 Gen Mills Inc Vinyl resins plasticized with cyano esters
    US3133954A (en) * 1959-08-18 1964-05-19 Rohm & Haas Process for preparing chlorinated cyanoesters
    US3110723A (en) * 1959-08-18 1963-11-12 Rohm & Haas Process for preparing monochlorinated cyanoesters
    US3444161A (en) * 1965-09-02 1969-05-13 Shionogi Seiyaku Kk Alkyl cyano aluminum compounds and process for introducing a cyano group into an alpha,beta unsaturated carbonyl compound
    DE1793347A1 (en) * 1968-09-04 1972-02-03 Dynamit Nobel Ag Process for the preparation of substituted cyanobutyric acids
    JPS54100316A (en) * 1978-01-25 1979-08-08 Meiji Seika Kaisha Ltd Preparation of derivative of aminobutyric acid
    US4428887A (en) * 1982-07-14 1984-01-31 Monsanto Company Method of producing mono-substituted terminal diesters
    DE3227388A1 (en) * 1982-07-22 1984-01-26 Basf Ag, 6700 Ludwigshafen METHOD FOR PRODUCING (ALPHA) SUBSTITUTED SS-DICARBONYL, SS-CYANCARBONYL AND SS-DICYAN COMPOUNDS
    US4760089A (en) * 1985-09-09 1988-07-26 Smithkline Beckman Corporation Irreversible dopamine-β-hydroxylase inhibitors
    US5132451A (en) * 1989-08-25 1992-07-21 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
    US5077425A (en) * 1990-04-02 1991-12-31 E. I. Du Pont De Nemours And Company Nitrile-accelerated hydrocarboxylation
    US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
    US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
    RU94046105A (en) * 1992-05-20 1997-06-20 Нортвестерн Юниверсити (Us) ANALOGS OF γ-AMINOBUTYRIC ACID AND L-GLUTAMIC ACID AND METHODS OF THEIR SYNTHESIS

    Cited By (2)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    CN105348125A (en) * 2015-11-26 2016-02-24 太仓运通生物化工有限公司 Method for synthesizing Pregabalin by taking isovaleraldehyde as raw material
    CN111333529A (en) * 2018-12-19 2020-06-26 北京万全德众医药生物技术有限公司 Preparation method of pregabalin

    Also Published As

    Publication number Publication date
    GEP19991870B (en) 1999-12-06
    HUP9802504A2 (en) 1999-02-01
    HU0500934D0 (en) 2005-12-28
    SK164597A3 (en) 1998-05-06
    JP3874306B2 (en) 2007-01-31
    NZ308319A (en) 2000-02-28
    PL323795A1 (en) 1998-04-27
    SK283507B6 (en) 2003-08-05
    EE9700320A (en) 1998-06-15
    NZ501628A (en) 2001-09-28
    US5637767A (en) 1997-06-10
    ATE210628T1 (en) 2001-12-15
    AU5792196A (en) 1996-12-30
    EP0830338A1 (en) 1998-03-25
    PL185425B1 (en) 2003-05-30
    SK282865B6 (en) 2003-01-09
    EE04053B1 (en) 2003-06-16
    WO1996040617A1 (en) 1996-12-19
    CZ384697A3 (en) 1998-03-18
    PL185560B1 (en) 2003-06-30
    CA2219150C (en) 2008-11-18
    CZ296895B6 (en) 2006-07-12
    US20010016665A1 (en) 2001-08-23
    SI0830338T1 (en) 2002-04-30
    CZ291147B6 (en) 2002-12-11
    HU228194B1 (en) 2013-01-28
    PL185557B1 (en) 2003-06-30
    US6046353A (en) 2000-04-04
    US5840956A (en) 1998-11-24
    JPH11506726A (en) 1999-06-15
    AU700091B2 (en) 1998-12-24
    ES2170231T3 (en) 2002-08-01
    HUP9802504A3 (en) 2000-06-28
    HU229957B1 (en) 2015-03-30
    DK0830338T3 (en) 2002-04-02
    DE69617948D1 (en) 2002-01-24
    PT830338E (en) 2002-04-29
    DE69617948T2 (en) 2002-06-13
    MX9708652A (en) 1998-06-30
    CA2219150A1 (en) 1996-12-19

    Similar Documents

    Publication Publication Date Title
    EP0830338B1 (en) Method of making 3-(aminomethyl)-5-methylhexanoic acid
    EP0828704B1 (en) Methods of making (s)-3-(aminomethyl)-5-methylhexanoic acid
    WO2008009897A1 (en) Process for preparing pregabalin and its opposite enantiomer
    EP2017273A1 (en) Process for the enantioselective preparation of pregabalin
    EP1912931A2 (en) Preparation of (s)-pregabalin-nitrile
    AU700091C (en) Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
    CA2219278C (en) Methods of making (s)-3-(aminomethyl)-5-methylhexanoic acid
    MXPA97008652A (en) Method for making acid (s) -3- (aminomethyl) -5-methylhexane
    WO2009127560A1 (en) Intermediates for the preparation of pregabalin and process for their preparation
    MXPA97008338A (en) Methods to make acid (s) -3- (aminomethyl) -5-methylhexane

    Legal Events

    Date Code Title Description
    PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

    Free format text: ORIGINAL CODE: 0009012

    17P Request for examination filed

    Effective date: 19971119

    AK Designated contracting states

    Kind code of ref document: A1

    Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

    AX Request for extension of the european patent

    Free format text: LT PAYMENT 971119;LV PAYMENT 971119;SI PAYMENT 971119

    17Q First examination report despatched

    Effective date: 19990427

    RTI1 Title (correction)

    Free format text: METHOD OF MAKING 3-(AMINOMETHYL)-5-METHYLHEXANOIC ACID

    GRAG Despatch of communication of intention to grant

    Free format text: ORIGINAL CODE: EPIDOS AGRA

    GRAG Despatch of communication of intention to grant

    Free format text: ORIGINAL CODE: EPIDOS AGRA

    GRAH Despatch of communication of intention to grant a patent

    Free format text: ORIGINAL CODE: EPIDOS IGRA

    GRAH Despatch of communication of intention to grant a patent

    Free format text: ORIGINAL CODE: EPIDOS IGRA

    GRAA (expected) grant

    Free format text: ORIGINAL CODE: 0009210

    AK Designated contracting states

    Kind code of ref document: B1

    Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

    AX Request for extension of the european patent

    Free format text: LT PAYMENT 19971119;LV PAYMENT 19971119;SI PAYMENT 19971119

    REF Corresponds to:

    Ref document number: 210628

    Country of ref document: AT

    Date of ref document: 20011215

    Kind code of ref document: T

    REG Reference to a national code

    Ref country code: CH

    Ref legal event code: EP

    REG Reference to a national code

    Ref country code: GB

    Ref legal event code: IF02

    REG Reference to a national code

    Ref country code: CH

    Ref legal event code: NV

    Representative=s name: SCHMAUDER & PARTNER AG PATENTANWALTSBUERO

    REG Reference to a national code

    Ref country code: IE

    Ref legal event code: FG4D

    REF Corresponds to:

    Ref document number: 69617948

    Country of ref document: DE

    Date of ref document: 20020124

    ET Fr: translation filed
    REG Reference to a national code

    Ref country code: DK

    Ref legal event code: T3

    REG Reference to a national code

    Ref country code: PT

    Ref legal event code: SC4A

    Free format text: AVAILABILITY OF NATIONAL TRANSLATION

    Effective date: 20020117

    REG Reference to a national code

    Ref country code: GR

    Ref legal event code: EP

    Ref document number: 20020400901

    Country of ref document: GR

    REG Reference to a national code

    Ref country code: ES

    Ref legal event code: FG2A

    Ref document number: 2170231

    Country of ref document: ES

    Kind code of ref document: T3

    PLBE No opposition filed within time limit

    Free format text: ORIGINAL CODE: 0009261

    STAA Information on the status of an ep patent application or granted ep patent

    Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

    26N No opposition filed
    REG Reference to a national code

    Ref country code: SI

    Ref legal event code: IF

    REG Reference to a national code

    Ref country code: CH

    Ref legal event code: PCAR

    Free format text: SCHMAUDER & PARTNER AG PATENT- UND MARKENANWAELTE VSP;ZWAENGIWEG 7;8038 ZUERICH (CH)

    REG Reference to a national code

    Ref country code: FR

    Ref legal event code: PLFP

    Year of fee payment: 20

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: LU

    Payment date: 20150423

    Year of fee payment: 20

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: ES

    Payment date: 20150519

    Year of fee payment: 20

    Ref country code: PT

    Payment date: 20150427

    Year of fee payment: 20

    Ref country code: DK

    Payment date: 20150424

    Year of fee payment: 20

    Ref country code: SE

    Payment date: 20150507

    Year of fee payment: 20

    Ref country code: CH

    Payment date: 20150428

    Year of fee payment: 20

    Ref country code: GB

    Payment date: 20150424

    Year of fee payment: 20

    Ref country code: DE

    Payment date: 20150601

    Year of fee payment: 20

    Ref country code: FI

    Payment date: 20150507

    Year of fee payment: 20

    Ref country code: MC

    Payment date: 20150429

    Year of fee payment: 20

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: IE

    Payment date: 20150427

    Year of fee payment: 20

    Ref country code: NL

    Payment date: 20150512

    Year of fee payment: 20

    Ref country code: GR

    Payment date: 20150427

    Year of fee payment: 20

    Ref country code: BE

    Payment date: 20150511

    Year of fee payment: 20

    Ref country code: FR

    Payment date: 20150424

    Year of fee payment: 20

    Ref country code: IT

    Payment date: 20150513

    Year of fee payment: 20

    Ref country code: AT

    Payment date: 20150424

    Year of fee payment: 20

    REG Reference to a national code

    Ref country code: DE

    Ref legal event code: R071

    Ref document number: 69617948

    Country of ref document: DE

    REG Reference to a national code

    Ref country code: DK

    Ref legal event code: EUP

    Effective date: 20160513

    REG Reference to a national code

    Ref country code: NL

    Ref legal event code: MK

    Effective date: 20160512

    REG Reference to a national code

    Ref country code: PT

    Ref legal event code: MM4A

    Free format text: MAXIMUM VALIDITY LIMIT REACHED

    Effective date: 20160513

    REG Reference to a national code

    Ref country code: CH

    Ref legal event code: PL

    REG Reference to a national code

    Ref country code: GB

    Ref legal event code: PE20

    Expiry date: 20160512

    REG Reference to a national code

    Ref country code: IE

    Ref legal event code: MK9A

    REG Reference to a national code

    Ref country code: AT

    Ref legal event code: MK07

    Ref document number: 210628

    Country of ref document: AT

    Kind code of ref document: T

    Effective date: 20160513

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: GB

    Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

    Effective date: 20160512

    Ref country code: IE

    Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

    Effective date: 20160513

    REG Reference to a national code

    Ref country code: ES

    Ref legal event code: FD2A

    Effective date: 20160826

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: PT

    Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

    Effective date: 20160519

    REG Reference to a national code

    Ref country code: GR

    Ref legal event code: MA

    Ref document number: 20020400901

    Country of ref document: GR

    Effective date: 20160514

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: ES

    Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

    Effective date: 20160514